Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Plasma-Cell Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06121843
What this trial is testing

Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187
Testing effectiveness (Phase 2)Active Not RecruitingNCT00871013
What this trial is testing

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Who this might be right for
Myeloma
University of Arkansas 160
Early research (Phase 1)Study completedNCT00722488
What this trial is testing

Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma

Who this might be right for
Hematologic MalignanciesMultiple MyelomaLymphoma+1 more
Millennium Pharmaceuticals, Inc. 56
Large-scale testing (Phase 3)UnknownNCT00003603
What this trial is testing

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Riverside Haematology Group 660
Testing effectiveness (Phase 2)Active Not RecruitingNCT03030261
What this trial is testing

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Washington University School of Medicine 25
Testing effectiveness (Phase 2)Ended earlyNCT00920556
What this trial is testing

A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sirtris, a GSK Company 24
Early research (Phase 1)Study completedNCT03068351
What this trial is testing

Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hoffmann-La Roche 24
Not applicableEnded earlyNCT03657251
What this trial is testing

MMRF CureCloud Research Initiative

Who this might be right for
Multiple Myeloma
Multiple Myeloma Research Foundation 1,105
Post-approval studies (Phase 4)WithdrawnNCT05183139
What this trial is testing

In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Takeda
Large-scale testing (Phase 3)Looking for participantsNCT07222761
What this trial is testing

Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 915
Testing effectiveness (Phase 2)Ended earlyNCT01078441
What this trial is testing

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

Who this might be right for
Refractory Multiple Myeloma
National Cancer Institute (NCI) 2
Very early researchLooking for participantsNCT04662294
What this trial is testing

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Who this might be right for
Acute Myeloid LeukemiaNon-hodgkin's LymphomaMultiple Myeloma
Zhejiang University 108
Testing effectiveness (Phase 2)Study completedNCT01793051
What this trial is testing

Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 88
Not applicableEnded earlyNCT02114827
What this trial is testing

Efficacy of a Patient Education Video

Who this might be right for
Leukemia, Not Otherwise SpecifiedMalignant Neoplasm
Virginia Commonwealth University 9
Not applicableTemporarily pausedNCT03752541
What this trial is testing

Efficacy and Safety Evaluation of BCMA-UCART

Who this might be right for
Multiple Myeloma
Bioray Laboratories 20
Early research (Phase 1)Study completedNCT03338972
What this trial is testing

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Fred Hutchinson Cancer Center 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT05014646
What this trial is testing

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Who this might be right for
Smoldering Plasma Cell Myeloma
City of Hope Medical Center 27
Testing effectiveness (Phase 2)Looking for participantsNCT06461988
What this trial is testing

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Who this might be right for
Multiple MyelomaPost Stem Cell Transplant
Stanford University 20
Testing effectiveness (Phase 2)Study completedNCT01355705
What this trial is testing

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Michaela Liedtke 14
Testing effectiveness (Phase 2)Ended earlyNCT03850522
What this trial is testing

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
Lene Meldgaard Knudsen 6
Next Page